Cannabis Law and Access in Philippines

A country built on prohibition , with a narrow medical exception

The Philippines executed more than 6,000 people in extrajudicial drug killings between 2016 and 2022, according to Human Rights Watch. That number sits with you. It is the context you need before any conversation about Philippine cannabis law makes sense.

And yet, quietly, a medical cannabis framework has existed there since 2019. The gap between that legislation and what it means in practice , who can access it, what compounds are legal, under what bureaucratic conditions , is where the interesting and often frustrating detail lives.

I'll be honest: I came to this topic sideways. I was cross-referencing how different Asia-Pacific jurisdictions handle cannabidiol scheduling while working on something else, and the Philippine framework stopped me for a good hour. The combination of a strict anti-drug statute sitting alongside a narrow compassionate-access channel reminded me structurally of where Australia sat in 2015; the tension between a prohibitionist default and a growing clinical pressure to carve out exceptions.

The Dangerous Drugs Act: the prohibitionist baseline

Republic Act 9165, the Comprehensive Dangerous Drugs Act of 2002, remains the foundational law. Cannabis (referred to as "marijuana" in the statute) sits in a prohibited category. Possession, sale, and cultivation carry penalties ranging from six years' imprisonment up to life imprisonment, depending on quantity and intent. The law draws no practical distinction between tetrahydrocannabinol-rich flower and non-intoxicating preparations, everything under the Cannabis sativa classification is caught by the same prohibition absent a specific lawful exemption.

That matters a great deal for understanding what Republic Act 11036 actually does and does not change.

Republic Act 11036, the medical cannabis law

Signed in July 2019, RA 11036; the "Medical Cannabis Compassionate Use Act", created a legal pathway for the use of cannabis preparations specifically described as "medical cannabis oil" in the text. The law is narrow by design. It does not legalise cannabis broadly. It does not permit cultivation by patients. It does not open a retail or dispensary market of the kind seen in parts of the United States or Canada.

What it does is establish a compassionate use framework, administered jointly by the Philippine Drug Enforcement Agency (PDEA), the Department of Health (DOH), and the Food and Drug Administration (FDA Philippines). The structure looks something like this:

• Patients with a qualified condition may apply for a compassionate special permit (CSP) through the PDEA.
• A licensed physician must issue a certification, and the patient is registered in a national database.
• Only preparations that have passed FDA Philippines review and hold a licence to operate are lawfully distributed.
• Importation from an approved foreign source is currently the primary supply pathway, since domestic cultivation for medical purposes remains under a separate, not-yet-fully-operational regulatory instrument.

In practice, the framework has moved slowly. Implementation rules were published in stages from 2019 onwards, and as of 2023 the number of registered patients remained in the low thousands, a fraction of those who had applied or sought access. Processing delays, cost barriers, and the practical difficulty of navigating multiple agency requirements have been widely noted by patient advocacy groups in the Philippines.

What does "medical cannabis oil" mean in the regulation?

This is where it gets chemically interesting. The RA 11036 framework focuses on preparations sometimes described in the implementing rules as "cannabidiol-dominant" oils, though the legislation uses the broader term "medical cannabis oil." Preparations must be manufactured under conditions that meet international good manufacturing standards; the Philippine FDA assesses these against standards broadly analogous to what we'd call Good Manufacturing Practice in the Australian context.

The THC content thresholds for permitted preparations, and whether higher-THC preparations can be accessed via the CSP pathway, has been a live policy question. The initial drafts of implementing rules were more restrictive around THC content; subsequent guidance has tried to accommodate the clinical reality that some preparations require a broader cannabinoid profile. Whether a given import application is approved depends substantially on the PDEA-DOH-FDA tripartite review, and that process has not been transparent in a way that makes it easy to predict outcomes.

For anyone researching how cannabinoids interact at the receptor level, the underlying pharmacology doesn't change with geography, the endocannabinoid system operates consistently across human populations, and the scheduling debate in any country is ultimately a policy argument, not a biological one.

Recreational use: still a serious criminal matter

Let me be direct here. Outside the compassionate use framework, cannabis remains a Schedule I prohibited substance under Philippine law. Possession of even small amounts can result in prosecution. The Duterte administration's drug war was particularly brutal in its application, and whilst the Marcos administration (post-2022) has taken a different public tone on drug policy, RA 9165 has not been repealed or substantially amended. Enforcement priorities may shift between administrations, but the legal exposure under the statute does not.

For Australian travellers or residents spending time in the Philippines: there is no personal use defence, no on-the-spot fine framework, and no tolerance zone. This is not comparable to parts of Europe where possession of small amounts attracts an administrative rather than criminal response.

Where the framework sits compared to regional neighbours

South-East Asia as a region remains predominantly prohibitionist, with Thailand's 2022 delisting of cannabis as a narcotic being the major exception, and that remains a contested policy. Singapore, Malaysia, and Indonesia all carry mandatory minimum sentences for cannabis-related offences. The Philippines sits roughly in the middle: stricter enforcement history than Thailand (post-2022), a more developed medical access framework on paper than Indonesia, but a practical access gap that is substantial.

The structural comparison I keep coming back to, from an access-pathway perspective, is actually closer to what Australia looked like between the passage of the Narcotic Drugs Amendment Act in 2016 and the point where the Special Access Scheme and Authorised Prescriber pathways genuinely began functioning at scale. The law existed; the operational machinery lagged. The Philippines may close that gap, or it may not; that depends entirely on domestic political will and DOH/PDEA resourcing.

In my view, the tripartite agency structure in the Philippines creates unnecessary administrative friction that is slowing patient access without delivering a commensurate regulatory benefit. A single-agency model, similar to what the TGA runs here, would almost certainly streamline CSP processing. Whether that observation ever makes it into a Senate review committee hearing in Manila is another question entirely.

Domestic cultivation and the pending regulatory layer

RA 11036 does contemplate a licensed domestic cultivation programme for medical purposes, this would allow Philippine soil to produce plants under strict PDEA oversight, reducing import dependency. As of the information available through mid-2024, that programme had not been fully operationalised. Draft rules had circulated, seed-to-sale tracking requirements had been outlined, but no licensed cultivators had received operational approval under the RA 11036 framework.

This is a significant gap. Reliance on imported preparations keeps costs high, limits product variety, and creates supply chain fragility. It also means the full downstream pharmacological diversity of the plant, including minor cannabinoids and the role of full-spectrum preparations; is largely inaccessible within the legal framework at the moment.

Trevor, my sourdough starter, has taught me that slow fermentation produces better results, but I'm not sure that lesson translates to drug regulation timelines. Some of these processes are just slow in ways that have real human costs.

What Australian researchers and travellers should know

A few practical points for anyone approaching this from an Australian perspective:

• Australian-prescribed cannabis preparations, whether accessed via the Special Access Scheme or an Authorised Prescriber; carry no legal recognition in the Philippines. Travelling with them is travelling with a controlled substance under RA 9165.
• The PDEA website (pdea.gov.ph) and DOH Philippines are the primary official sources for CSP application requirements. Neither the Australian TGA nor DFAT can assist with navigating Philippine access pathways.
• DFAT's Smartraveller advisory for the Philippines explicitly flags drug laws as a serious risk for Australian travellers and recommends reviewing local laws before travel.

The science of cannabinoids, the receptor pharmacology, the chemistry of CBD, the ongoing research into the endocannabinoid system, is a global conversation that doesn't stop at any border. The law, though, is intensely local. In the Philippines, those two realities are sitting at an uncomfortable distance from each other.

Sources

• License to Kill: Philippine Police Killings in Duterte's Drug War; Human Rights Watch
• Republic Act 11036: Medical Cannabis Compassionate Use Act, LawPhil Philippine Laws and Jurisprudence Databank
• Food and Drug Administration Philippines, fda.gov.ph
• Philippines Travel Advice; Smartraveller, Australian Government DFAT

, Marcus Hale, Regulatory researcher, TGA & access law